Publikationen

2011

• Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, Bartkowiak D, Hinkelbein W, Wiegel T (2011) Salvage radiotherapy after prostatectomy – What is the best time to treat? Radiother Oncol. in press.

• Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, Schneider U, Bottke D, Wiegel T. Second cancer after radiotherapy, 1981-2007. Radiother Oncol. 2011 [Epub ahead of print].

• Budäus L, Bolla M, Bossi A, Cozzarini C, Crook J, Widmark A, Wiegel T. Functional Outcomes and Complications Following Radiation Therapy for Prostate Cancer: A Critical Analysis of the Literature. Eur Urol. 2011 [Epub ahead of print].

• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan;59(1):61-71.

• Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V; ESMO Guidelines Working Group: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6:vi45-9.

• Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W: Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival : Results of a retrospective study. Strahlenther. Onkol. 2011,187:467-72.

• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F: EAU Guidelines on Prostate Cancer. Part I: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Actas Urol Esp. 2011 Jul 12. [Epub ahead of print]

• Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Actas Urol. Esp. 2011 Jul 12. [Epub ahead of print]

• Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2011,59:572-83.

2010

• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease.
  Eur Urol. 2010 Oct 28.  [Epub ahead of print]

• Wenz F, Martin T, Böhmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T. The German S3 Guideline Prostate Cancer : Aspects for the Radiation Oncologist.
  Strahlenther Onkol. 2010;186:531-4

• Kornmann M, Staib L, Wiegel T, Kreuser ED, Kron M, Baumann W, Henne-Bruns D, Link KH. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-a.
  Br J Cancer. 2010;103:1163-72.

• Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
  J Clin Oncol. 2010;28:4199-206.

• Welte B, Suhr P, Bottke D, Bartkowiak D, Dörr W, Trott KR, Wiegel T. Second Malignancies in High-Dose Areas of Previous Tumor Radiotherapy.
  Strahlenther Onkol. 2010;186:175-79.

• Kilian HG, Kazda M, Király F, Kaufmann D, Kemkemer R, Bartkowiak D: On the structure-bounded growth processes in plant populations.
  Cell Biochem Biophys. 2010;57:87-100.

• Bottke D, WiegelT: Radiotherapy and Prostate Cancer: Quo Vadis?
  Eur Urol. 2010;Suppl 9,394-400

• Martin T, Wenz F, Böhmer D, Sedlmayer F, Hinkelbein W, Henkel TO, Miller K, Wiegel T: [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy]
  Urologe A. 2010 Feb;49(2):216-20.

• Böhmer D, Wenz F, Martin T, Sedlmayr F, Hinkelbein W, Wiegel T: [Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer]
  Urologe A. 2010 Feb;49(2):211-5.

• Grimm MO, Thomas C, Fröhner M, Wiegel T, Heidenreich A, Thüroff JW, Wirth M: [Pelvic lymphadenectomy and radical prostatectomy. Recommendations of the German S3 guideline]
  Urologe A. 2010 Feb;49(2):206-10.

• Welte B, Suhr P, Bottke D, Bartkowiak D, Dörr W, Trott KR, Wiegel T: Second malignancies in high-dose areas of previous tumor radiotherapy.
  Strahlenther Onkol. 2010 Mar;186(3):174-9.

• Meisner J, Meyer A, Polivka B, Karstens JH, Bremer M: Outcome of moderately dosed radiosurgery for limited brain metastases. Report of a single-center experience.
  Strahlenther Onkol. 2010 Feb;186(2):76-81.

2009

• Reiter R, Deutschle T, Wiegel T, Riechelmann H, Bartkowiak D: Absence of inflammatory response from upper airway epithelial cells after X irradiation.
  Radiat Res. 2009 Mar;171(3):274-82.

• Bottke D, de Reijke TM, Bartkowiak D, Wiegel T: Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer.
  Eur J Cancer. 2009 Sep;45 Suppl 1:148-57.

• Bartkowiak D, Stempfhuber M, Wiegel T, Bottke D: Radiation- and chemoinduced multidrug resistance in colon carcinoma cells.
  Strahlenther Onkol. 2009 Dec;185(12):815-20.

• Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
  J Clin Oncol. 2009 Jun 20;27(18):2924-30.

• Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W:  Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
  Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1009-16.

• Sautter-Bihl ML, Sedlmayer F, Wiegel T: Postoperative radiotherapy for advanced prostate cancer: improved local control translates into increased survival.
  Strahlenther Onkol. 2009 Aug;185(8):485-7.

• de Reijke TM, Wiegel T: Treatment of local progression following radiotherapy.
  Eur J Cancer. 2009 Sep;45 Suppl 1:140-7.

• Steinmann D, Schäfer C, van Oorschot B, Wypior HJ, Bruns F, Bölling T, Sehlen S, Hagg J, Bayerl A, Geinitz H, Hipp M, Vordermark D: Effects of radiotherapy for brain metastases on quality of life (QoL). Prospective pilot study of the DEGRO QoL working party.
  Strahlenther Onkol. 2009 Mar;185(3):190-7.

2008

• Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, Hinkelbein W, Keilholz U: Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines.
  Radiat Res. 2008 Jul;170(1):41-8.

• Bottke D, Wiegel T: Postoperative adjuvant radiotherapy - standard of care?
  Front Radiat Ther Oncol. 2008;41:32-8.

• Bottke D, Wiegel T: pT3R1 prostate cancer : Immediate or delayed radiotherapy after radical prostatectomy?
  Urologe A. 2008 Nov;47(11):1431-5.

• Kreusel KM, Bechrakis NE, Wiegel T, Krause L, Foerster MH: Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer.
  Acta Ophthalmol. 2008 Aug;86(5):515-9.

• Kilian HG, Bartkowiak D, Kaufmann D, Kemkemer R: The general growth logistics of cell populations.
  Cell Biochem Biophys. 2008;51(2-3):51-66.

• Söhn M, Birkner M, Chi Y, Wang J, Di Y, Berger B, Alber M: Model-independent, multimodality deformable image registration by local matching of anatomical features and minimization of elastic energy.
  Med Phys. 2008 Mar;35(3):866-78.

2007

• Kreusel KM, Bechrakis NE, Krause L, Wiegel T, Foerster MH: Incidence and clinical characteristics of symptomatic choroidal metastasis from breast cancer.
  Acta Ophthalmol Scand. 2007 May;85(3):298-302.

• Bottke D, Wiegel T, Kreienberg R, Kurzeder C, Sauer G: Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy?
  Strahlenther Onkol. 2007 Nov;183(11):600-4.

• Lohr F, Boda-Heggemann J, Wenz F, Wiegel T: Image-guided radiotherapy for prostate cancer.
  Aktuelle Urol. 2007 Sep;38(5):386-91; discussion 385.

• Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE: Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
  BJU Int. 2007 Oct;100(4):786-93.

• Bottke D, Wiegel T: Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects.
  Urol Int. 2007;78(3):193-7..

• Bottke D, Wiegel T: Percutaneous radiotherapy for low-risk prostate cancer: options for 2007.
  World J Urol. 2007 Mar;25(1):53-7.

• Bottke D, Bathe K, Wiegel T, Hinkelbein W: Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck.
  Strahlenther Onkol. 2007 Mar;183(3):128-32.

• Bartkowiak D, Hipp PR, Mendonca MS, Röttinger EM. A radioprotective effect of imatinib (Gleevec) in human squamous carcinoma cells.
  Strahlenther Onkol. 2007 Aug;183(8):432-9.

• Birkner M, Thorwarth D, Poser A, Ammazzalorso F, Alber M: Analysis of the rigid and deformable component of setup inaccuracies on portal images in head and neck radiotherapy.
  Phys Med Biol. 2007 Sep 21;52(18):5721-33.